Literature DB >> 25308174

Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis.

Yuan Li1, Shasha Wu1, Shanshan Xiong1, Gaoliang Ouyang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25308174     DOI： 10.1016/j.jhep.2014.10.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  9 in total

1.  Periostin on the road to nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  Endocrine       Date:  2015-11-19       Impact factor: 3.633

2.  Circulating periostin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Athanasios Papatheodorou; Panagiotis Kokkoris; Evangelos Terpos
Journal:  Endocrine       Date:  2016-10-13       Impact factor: 3.633

3.  Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study.

Authors:  Jin-Zhou Zhu; Hua-Tuo Zhu; Yi-Ning Dai; Chun-Xiao Li; Zhi-Yun Fang; De-Jian Zhao; Xing-Yong Wan; Yu-Ming Wang; Fang Wang; Chao-Hui Yu; You-Ming Li
Journal:  Endocrine       Date:  2015-09-11       Impact factor: 3.633

4.  Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via αv integrin interaction.

Authors:  Akiko Sugiyama; Keishi Kanno; Norihisa Nishimichi; Shoichiro Ohta; Junya Ono; Simon J Conway; Kenji Izuhara; Yasuyuki Yokosaki; Susumu Tazuma
Journal:  J Gastroenterol       Date:  2016-04-04       Impact factor: 7.527

Review 5.  The multifaceted role of periostin in priming the tumor microenvironments for tumor progression.

Authors:  Dan Cui; Zhengjie Huang; Yingfu Liu; Gaoliang Ouyang
Journal:  Cell Mol Life Sci       Date:  2017-09-07       Impact factor: 9.261

6.  Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects.

Authors:  Zhen Yang; Hongmei Zhang; Yixin Niu; Weiwei Zhang; Lingfei Zhu; Xiaoyong Li; Shuai Lu; Jiangao Fan; Xiaoying Li; Guang Ning; Li Qin; Qing Su
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

7.  Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development.

Authors:  Kosuke Takeda; Ryuichi Noguchi; Mitsuteru Kitade; Tadashi Namisaki; Kei Moriya; Hideto Kawaratani; Yasushi Okura; Kosuke Kaji; Yosuke Aihara; Akitoshi Douhara; Norihisa Nishimura; Yasuhiko Sawada; Kenichiro Seki; Hitoshi Yoshiji
Journal:  Mol Med Rep       Date:  2017-08-24       Impact factor: 2.952

Review 8.  Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment.

Authors:  Claire E McQuitty; Roger Williams; Shilpa Chokshi; Luca Urbani
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

9.  Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Carlo Smirne; Violante Mulas; Matteo Nazzareno Barbaglia; Venkata Ramana Mallela; Rosalba Minisini; Nadia Barizzone; Michela Emma Burlone; Mario Pirisi; Elena Grossini
Journal:  Diagnostics (Basel)       Date:  2020-11-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.